title: Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.
abstract: BACKGROUND
  The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known.
  
  
  METHODS
  Data from 87 patients with MDS (n=67) and chronic myelomonocytic leukemia (n=.20) after failure of decitabine regimens were reviewed.
  
  
  RESULTS
  After a median follow-up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12-month survival rate was 28%. The estimated 12-month survival rates were 27%, 33%, and 33%, respectively, for patients with high-risk, intermediate-2-risk, and intermediate-1-risk disease (P=.99) by the International Prognostic Scoring System. The estimated 12-month survival rates were 100%, 54%, 41%, and 18%, respectively, for patients with low-risk, intermediate-1-risk, intermediate-2-risk, and high-risk disease according to The University of Texas M. D. Anderson Cancer Center risk model (P=.01).
  
  
  CONCLUSIONS
  The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure.
authors.affiliation: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. ejabbour@mdanderson.org
authors.forename: Elias
authors.initials: E
authors.lastname: Jabbour
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.forename: Nicolas
authors.initials: N
authors.lastname: Batty
authors.forename: Jenny
authors.initials: J
authors.lastname: Shan
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
authors.forename: Farhad
authors.initials: F
authors.lastname: Ravandi
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Issa
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077209:Decitabine; D006801:Humans; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy* / Q000401:mortality; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000077209:Decitabine; D001374:Azacitidine